Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 75

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 75
---
 commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws
also involve the improper use of information obtained in the course of clinical validation, which could result in regulatory sanctions
and cause serious harm to Renovaro Cube’s reputation. Renovaro Cube has adopted a code of business conduct and ethics, but it is
not always possible to identify and deter misconduct by employees and third parties, and the precautions Renovaro Cube takes to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Renovaro Cube from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions
are instituted against Renovaro Cube, and Renovaro Cube is not successful in defending itself or asserting its rights, those actions could
have a significant impact on Renovaro Cube’s business, including the imposition of significant fines or other sanctions. Even if
it is later determined after an action is instituted against Renovaro Cube that Renovaro Cube was not in violation of these laws, Renovaro
Cube may be faced with negative publicity, incur significant expenses defending its actions and have to divert significant management
resources from other matters.

Risks Related To Our Business Operations

Our business plan may lead to the initiation of one or more product development programs, the discontinuation of one or more development programs, or the execution of one or more transactions that investors do not agree with or that investors do not perceive as favorable to their investment in our Common Stock.

We are pursuing a strategy to, dependent upon raising sufficient funding to
do so, leverage our clinical experience and expertise for the clinical development and regulatory approval of our gene therapy product
candidates and advance our AI-driven healthcare technology. As part of our ongoing business strategy, we continue to explore potential
opportunities to acquire or license new product candidates and to collaborate on our existing products in development. We cannot be certain
that our product candidates will be successfully developed, or that the early clinical trial results of our therapeutic product candidates
will be predictive of future clinical trial results. During 2022, we decided to abandon our pan-coronavirus and influenza pipelines as
the results did not support further development. We again may determine at any time that one or more of our in-licensed product candidates
is not suitable for continued development due to cost, feasibility of obtaining regulatory approvals or any other reason, and may terminate
the related license.

Our business plan